| Attributes | Values |
|---|
| rdf:type
| |
| rdfs:label
| - Pegylated Liposomal Doxorubicin Hydrochloride
|
| rdfs:subClassOf
| |
| Semantic_Type
| |
| Preferred_Name
| - Pegylated Liposomal Doxorubicin Hydrochloride
|
| NSC_Code
| |
| UMLS_CUI
| |
| Accepted_Therapeutic_Use_For
| - Refractory metastatic carcinoma of the ovary; AIDS-related Kaposi's sarcoma; breast cancer; relapsed/refractory multiple myeloma (with bortezomib).
|
| In_Clinical_Trial_For
| - Advanced or metastatic soft tissue sarcoma; adenocarcinoma of the prostate; relapsed or persistent aggressive hematologic malignancies; advanced solid tumors; advanced or recurrent breast cancer
- Persistent or recurrent cervical cancer; recurrent ovarian cancer; stage III fallopian tube cancer; primary peritoneal cancer; endometrial cancer; AIDS-related Kaposi's sarcoma
|
| ALT_DEFINITION
| - A form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin. Doxil is used to treat ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma in patients whose disease has not gotten better after treatment with other anticancer drugs. It may be used together with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Doxil is a type of anthracycline antitumor antibiotic.NCI-GLOSS
|
| PDQ_Open_Trial_Search_ID
| |
| PDQ_Closed_Trial_Search_ID
| |
| Legacy_Concept_Name
| - Doxorubicin_Hydrochloride_Liposome
|
| FULL_SYN
| - DOXILSYDTPNSC0712227
- S-Liposomal DoxorubicinSYNCI
- Pegylated Doxorubicin HCl LiposomeSYNCI
- Liposomal-Encapsulated DoxorubicinSYNCI
- Doxorubicin Hydrochloride LiposomeSYNCI
- Doxorubicin HCl LiposomeSYNCI
- Liposomal Doxorubicin HydrochlorideSYNCI
- Pegylated Liposomal Doxorubicin HydrochloridePTNCI
- DoxilPTNCI-GLOSSCDR0000512797
- (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-tri-hydroxy-1-methoxy-5,12-naphthacenedione HydrochlorideSNNCI
- Dox-SLPTNCI-GLOSSCDR0000560138
- EvacetPTNCI-GLOSSCDR0000560137
- DoxilBRNCI
- DOX-SLBRNCI
- EvacetBRNCI
- CaelyxFBNCI
- LipoDoxPTNCI-GLOSSCDR0000560139
- doxorubicin hydrochloride liposomePTNCI-GLOSSCDR0000560136
- LipoDoxBRNCI
- Stealth Liposomal DoxorubicinSYNCI
- DoxilenFBNCI
- TLC D-99CNNCI
- liposomal doxorubicin hydrochloridePTNCI-GLOSSCDR0000663502
- Liposomal AdriamycinSYNCI
|
| DEFINITION
| - A liposome-encapsulated preparation of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between DNA base pairs, thereby hinders the movement of replication machinery along DNA strands, as well as blocks the activity of topoisomerase II during replication. As a result, this agent causes DNA adducts formation, renders single- and double-stranded DNA breakages that induce DNA repair and or apoptotic processes. Doxorubicin also generates reactive oxygen species that leads to cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCl improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. A liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs.NCI
|
| code
| |
| http://linked.open...y/mesh/hasConcept
| |
| is someValuesFrom
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)